SCHEMBL12419258

SCHEMBL12419258

OB(O)c1ccc2cc(Oc3ccccn3)ccc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.51
CA2 P00918 2/20 0.51
SCN7A Q01118 6/20 0.45
KCNH2 Q12809 6/20 0.45
SCN5A Q14524 1/20 0.42
SCN2A Q99250 1/20 0.42
SCN8A Q9UQD0 1/20 0.42
TLR4 O00206 1/20 0.42
TLR2 O60603 1/20 0.42
PTGS2 P35354 2/20 0.42
EGLN2 Q96KS0 1/20 0.40
EGLN1 Q9GZT9 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
RAB9A P51151 1/20 0.40
LTA4H P09960 1/20 0.39
KDM4E B2RXH2 1/20 0.39
PDE10A Q9Y233 1/20 0.39
MAP4K4 O95819 1/20 0.38
HAO1 Q9UJM8 1/20 0.38
GRM5 P41594 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16344571 0.85 CA1 (0.58) CA1CA2TLR4TLR2PTGS2
SCHEMBL29955750 0.85 CA1 (0.58) CA1CA2TLR4TLR2PTGS2
SCHEMBL12419260 0.83 RAB9A (0.58) CA1CA2TLR4TLR2HRH3
SCHEMBL12419254 0.81 SCN7A (0.44) CA1CA2SCN7AKCNH2SCN5A
SCHEMBL12419259 0.81 KDM4E (0.47) CA1CA2PTGS2HRH3RAB9A
SCHEMBL5686998 0.80 SCN7A (0.47) SCN7AKCNH2SCN5ASCN2ASCN8A
SCHEMBL8437226 0.77 CA1 (0.71) CA1CA2LTA4H
SCHEMBL1129299 0.76 THRB (0.55) SCN7AKCNH2SCN5ASCN2ASCN8A
SCHEMBL11143982 0.74 PTGS2 (0.57) TLR4TLR2PTGS2HRH3RAB9A
SCHEMBL21501382 0.74 MEN1 (0.47) SCN7AKCNH2SCN5ASCN2ASCN8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 US disclosed
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 US disclosed
WO-2009126691-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC (US) 2009-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 CA1 822/4885CA2 1487/4885SCN7A 2253/4885
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 CA1 822/4885CA2 1487/4885SCN7A 2253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.